COSMO Pharmaceuticals SA Share Price Swiss Exchange
Equities
LU1202320294
Pharmaceuticals
End-of-day quote
Other stock markets
|
||
- CHF | - |
|
18/06 | Switzerland's Cosmo Pharmaceuticals Receives Drug Registration Certificate for Lumeblue in China | MT |
03/06 | Cosmo Pharmaceuticals Swings to Loss in FY23; Revenue Down | MT |
Sales 2024 * | 26Cr 28Cr 26Cr 2.37TCr | Sales 2025 * | 24Cr 26Cr 24Cr 2.17TCr | Capitalization | 117.45Cr 126.36Cr 114.18Cr 11TCr |
---|---|---|---|---|---|
Net income 2024 * | 12Cr 13Cr 12Cr 1.11TCr | Net income 2025 * | 7.6Cr 8.18Cr 7.39Cr 682.95Cr | EV / Sales 2024 * | 4 x |
Net cash position 2024 * | 12Cr 13Cr 12Cr 1.07TCr | Net cash position 2025 * | 21Cr 23Cr 20Cr 1.89TCr | EV / Sales 2025 * | 3.99 x |
P/E ratio 2024 * |
9.55
x | P/E ratio 2025 * |
12.9
x | Employees | - |
Yield 2024 * |
2.87% | Yield 2025 * |
1.58% | Free-Float | 44.36% |
Latest transcript on COSMO Pharmaceuticals SA
Managers | Title | Age | Since |
---|---|---|---|
Niall Donnelly
DFI | Director of Finance/CFO | 52 | 01/16/01 |
Chairman | 61 | 01/06/01 | |
Chief Tech/Sci/R&D Officer | 54 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 69 | 01/97/01 | |
Director/Board Member | 69 | 01/12/01 | |
Chairman | 61 | 01/06/01 |
1st Jan change | Capi. | |
---|---|---|
+55.55% | 82TCr | |
+40.09% | 63TCr | |
-6.83% | 35TCr | |
+17.15% | 32TCr | |
+7.09% | 29TCr | |
+13.53% | 24TCr | |
+1.19% | 22TCr | |
+13.06% | 22TCr | |
+7.87% | 17TCr |